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In recent years there has been a resurgence of interest in brain barriers and various
roles their intrinsic mechanisms may play in neurological disorders. Such studies
require suitable models and markers to demonstrate integrity and functional changes
at the interfaces between blood, brain, and cerebrospinal fluid. Studies of brain barrier
mechanisms and measurements of plasma volume using dyes have a long-standing
history, dating back to the late nineteenth-century. Their use in blood-brain barrier studies
continues in spite of their known serious limitations in in vivo applications. These were
well known when first introduced, but seem to have been forgotten since. Understanding
these limitations is important because Evans blue is still the most commonly used marker
of brain barrier integrity and those using it seem oblivious to problems arising from its
in vivo application. The introduction of HRP in themid twentieth-century was an important
advance because its reaction product can be visualized at the electron microscopical
level, but it also has limitations. Advantages and disadvantages of these markers will be
discussed together with a critical evaluation of alternative approaches. There is no single
marker suitable for all purposes. A combination of different sized, visualizable dextrans
and radiolabeled molecules currently seems to be the most appropriate approach for
qualitative and quantitative assessment of barrier integrity.
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INTRODUCTION
The realization that brain barriers may play a critical role in a wide range of neurological disorders
prompted a renewed interest in studies of their function and integrity (Saunders et al., 2008). Such
studies require suitable models and especially markers to demonstrate integrity of the interfaces
between the blood, the brain and the cerebrospinal fluid, CSF. Similarly markers are also required
for the study of barriers in the developing brain and in its evolution, which are the main focus of the
Frontiers Topic “Ontogeny and Phylogeny of Brain Barrier Mechanisms.” Dyes have a venerable
history dating back to the end of the nineteenth-century, in studies of brain barrier mechanisms
Abbreviations: CNS, central nervous system; CSF, cerebrospinal fluid; HRP, horseradish peroxidase.
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in both the developing and adult brain, although many ascribe
incorrectly the first use of dyes for this purpose to Ehrlich in
the mid nineteenth-century or to Goldmann (1909, 1913), in
the early twentieth century (see Saunders et al., 2014). In times
when there were no alternatives it seems reasonable that dyes
should have been used as markers for brain barrier integrity,
similar to their use in cardiovascular studies for measurement
of plasma volume (Dawson et al., 1920). Particularly in the
latter field scientists were well aware of the limitations of
dyes and as soon as more satisfactory alternatives became
available, notably radiolabeled proteins such as albumin, dyes
were rapidly abandoned. In striking contrast, the use of dyes
remained widespread in blood-brain barrier field in spite of
their limitations, which have been well described since the mid
twentieth-century. One dye in particular, Evans blue (Figure 1)
is still the most commonly used marker of brain barrier integrity
(Figure 2) and its use has increased substantially in recent years
(Figure 3). Limitations of Evans blue as applied to studies of
brain barriers, as well as of other dyes, will be reviewed here
together with their properties. Another commonly used marker
for brain barrier integrity is HRP (introduced in mid twentieth-
century for electron microscopy studies by Straus (1959), Reese
and Karnovsky (1967), and Brightman and Reese (1969) will also
be discussed in this review.
The characteristics of an “ideal” marker for evaluating brain
barrier integrity are that it should be metabolically inert, non-
toxic, not bound to other molecules such as proteins in plasma or
tissues, be available in a range of molecular sizes, have the ability
to be visualized in the range from the naked eye to the electron
FIGURE 1 | Evans blue. As used at University College London, Department
of Physiology circa 1960 for in vivo plasma volume estimation.
microscopical level and be reliably quantifiable. The only merit
of Evans blue dye is that is visible to the unaided eye and can
thus give a gross indication of its distribution. However, it fails
on all other counts. Thus, studies using only Evans blue should no
longer be published, as there are much better markers available.
There is no single marker currently available that fulfills
all of the specified criteria, however different molecular sized
dextrans labeled with either biotin or a fluorescent tag come
close. Their main limitation is probably that they are tedious to
quantify; for this purpose it is better to use radiolabeled markers,
which are available in a wide range of molecular sizes but have
the disadvantage that currently they cannot be visualized with
sufficient resolution. Thus, a combination of different dextrans
and radiolabeled molecules is currently the most appropriate
approach to assessing barrier integrity in the developing or
pathological brain.
USE OF DYES FOR ESTIMATION OF
BLOOD VOLUME
A summary of this field is included because it was the studies
of the properties of dyes in circulating blood as established
by cardiovascular physiologists, which provided much of the
later justification for their use by blood-brain barrier biologists.
The significance of this is that in the early blood-brain barrier
studies it was not well appreciated that the dyes being used,
such as trypan blue, bind to proteins in plasma, although
there were some early hints that this might be the case (see
review by Saunders et al., 2014). The earliest dye dilution
estimation of plasma volume appears to be Keith et al. (1915).
These authors highlighted the unsatisfactory, unreliable and
potentially injurious methods previously used, which included
bleeding to death (of convicts) and inhalation of, or injection of
blood samples saturated with carbon monoxide. They proposed
the alternative method of a non-toxic, slowly absorbable dye
that remained in the circulation and suggested a colorimetric
determination of its concentration in plasma by comparison
with a mixture of dye and serum. On the advice of Dr. Evans
in the Anatomical Department (University of California, San
Francisco) Keith et al. (1915) used vital red, which Evans
supplied. This resulted in several extensive published studies
in dogs and humans. In later work in dogs brilliant vital red
was used (Hooper et al., 1920; Smith, 1920). This dye had a
number of disadvantages including difficulty in identifying when
haemolysis had occurred in the blood samples. Dawson et al.
(1920) investigated a series of dyes and concluded that the blue
azo dye (T-1824) was slightly superior to all the vital red dyes
tested. T-1824 was one of a large series of azo dyes developed in
the late nineteenth early twentieth centuries by the German dye
industry. T-1824 was its industrial code number. It is so named
because it can be synthesized by coupling together one mole of
diazotized o-toluidine and two moles of τ-amino-8-naphthol-2,
4-disulfonic acid (Allen and Orahovats, 1950).
One of the co-authors of Dawson et al. (1920) was Evans. The
name of the dye was much later changed from T-1824 to Evans
blue in recognition of his contributions to the use of dyes in
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FIGURE 2 | Papers in PubMed using different blood-brain barrier markers since 1953. One curiosity is that radiolabeled albumin was used more than a decade
(Ashkenazy and Crawley, 1953) before the first use of Evans blue (Rössner and Temple, 1966) but has only been infrequently used since then compared to Evans blue.
FIGURE 3 | Numbers of papers by year listed in PubMed for “blood-brain barrier Evans blue.” Note the very steep increase in the past 10 years; note also
that the value for 2015 is for only 9 months of the year. Thus, the use of Evans blue is still clearly increasing substantially.
animal studies; this designation has been suggested to have been
introduced by the Eastman Kodak Company, which marketed
the dye with this name (Cooksey, 2013). However, this name was
deplored by Gregersen and Stewart (1938) and Gregersen’s group
persisted with the original designation of T-1824 right up to their
last publication in the field (Gregersen and Rawson, 1959). In the
rest of the cardiovascular field the designation T-1824 is rarely
used unless in combination with Evans blue and is not used at
all in the blood-brain barrier field. To avoid confusion, when
discussing early literature in which only the designation T-1824
has been used, we have retained it in the form: T-1824 (Evans
blue).
A key criterion for a suitable dye was that it remained in
the circulation at a constant level for several minutes (optimum
was considered to be 4min). Many of the dyes were found to
be unsuitable because they disappeared from the blood rapidly,
in some cases via the kidneys. The authors had no explanation
for this difference compared to the azo dyes like T-1824 (Evans
blue), which was relatively stable in the blood. It seems most
likely that the excreted dyes, in contrast to Evans blue, were
not bound to plasma proteins, see below. The conclusion of
Dawson and his colleagues was that T-1824 (Evans blue) was
marginally superior to previously used vital red dyes and others
that they tested for measurement of plasma (blood) volume
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because colorimetric estimation was both easier and more
accurate.
One of the first uses of T-1824 (Evans blue) in humans
appears to have been by Gregersen and Stewart (1938). Prior
to its introduction various red dyes or trypan blue were used.
One advantage of T-1824 (Evans blue) was that much smaller
concentrations could be estimated; thus some clinicians judged
it to be superior to trypan blue because the large amount of that
dye required for plasma volume estimations gave the patients a
blue tinge, thus adding a cyanotic color to their already rather
sickly appearance (Gregersen, 1938). The use of T-1824 (Evans
blue) for estimation of plasma volume was extensively studied
by Gregersen and colleagues over the period from 1933 to 1956.
Gregersen (1938) in particular seems to have been preoccupied
with the need to develop more accurate colorimetric methods
than those of Keith et al. (1915) and modified by Smith (1920)
and by Dawson et al. (1920). This was prompted by his initial
studies undertaken at Harvard Medical School on the effects of
thirst and reduced salivary flow on plasma volume in which he
found these methods to give results that were of “questionable
accuracy” (Gregersen, 1932). With a fortitude that would
probably not be tolerated by modern grant agencies, he spent
the next 5 years improving the method, with a particular focus
on colorimetric methods used for measuring concentrations of
vital red dyes or T-1824 in plasma. He concluded that T-1824
(Evans blue) was a substantially better dye for plasma volume
measurements partly because much lower concentrations were
required but also because haemolysis was much less of a problem
for colorimetric measurements. Gregersen and colleagues at
Columbia University published extensively on the evaluation and
use of T-1824 (Evans blue) with comparisons with radioisotopic
methods once these were introduced (reviewed in Gregersen
and Rawson, 1959). Since that time T-1824 (Evans blue) has
largely been replaced by radio-iodinated human serum albumin
for indicator dilution estimations of plasma volume (Margouleff,
2013). This is in contrast to the persistence in the use of Evans
blue in studies of blood-barrier barrier integrity to the present
time; this is in spite of a similar availability of better methods for
many years, as discussed below. One paper from the Columbia
group of particular relevance for blood-brain barrier studies is
that of Rawson (1943) not least because it has frequently been
mis-cited. It provided a detailed analysis of the concentration
dependence of binding of Evans blue to human albumin, but
also provided evidence of binding to globulins. Because of the
importance of this paper for blood brain barrier permeability it
will be considered in some detail in a separate section on dye
binding to plasma proteins, below.
EVANS BLUE FOR ASSESSMENT OF
BLOOD-BRAIN BARRIER INTEGRITY
One of the earliest uses of Evans blue for blood-brain barrier
experiments appears to be that of Rössner and Temple (1966);
these authors cite Bauer et al. (1956) as having used Evans
blue, although Bauer et al. (1956) actually used Geigy Blau, the
properties of which seem to be poorly researched (Gregersen
and Rawson, 1959). Rössner and Temple (1966) were primarily
concerned with efforts to develop a method for measuring Evans
blue in tissue for which purpose they used about 300 rats and
50 guinea pigs. They do not appear to have considered the
appropriate concentration to use or in what form the dye was
present, although they do appear to have been aware of at least
some of the papers published by Gregersen and colleagues. They
used a large amount of dye (1ml, 2% Evans blue per 100 g
body weight) compared to the Gregersen group (e.g., 0.005–
0.01ml/100 g body weight, Gregersen and Stewart, 1938). It is
unclear why such a large amount of dye was used by Rössner
and Temple (1966) and in most subsequent studies by others,
given that an important reason for using Evans blue for blood
volume studies was that a much smaller amount of dye was
required (Gregersen, 1938). Possibly it followed on from the
protocols used for many years from the original experiments
of Goldmann (1913) in which trypan blue was used to study
blood-brain barrier permeability. Goldmann (1913) injected cats
intravenously with 30–50ml 1% trypan blue. In more recent
times dye concentrations have usually been 2–4% but in lesser
volumes. It is frequently stated in blood-brain barrier studies
that Evans blue binds rapidly, tightly and exclusively to plasma
albumin (Reeve, 1957; Stoelinga and vanMunster, 1967;Wolman
et al., 1981; Manaenko et al., 2011; Yen et al., 2013). However,
this is not the case as will be considered below. The problems of
using Evans blue as a marker for blood-brain barrier dysfunction
can be summarized as (i) the likelihood of a substantial amount
of free dye being present in an animal following the amounts
injected, (ii) lack of specific binding to albumin (although this
is widely believed, to the extent that many authors assume that
the concentration of Evans blue in the brain is synonymous with
penetration of albumin across a disrupted blood-brain barrier),
(iii) injection of dye dissolved in “physiological saline” or other
physiological solution, which have been suggested to affect the
structure of the dye, (iv) there is evidence that Evans blue binds
to tissues. (v) attempts to make quantitative assessments of
damage to the blood-brain barrier in the brain are confounded by
problems with the various spectroscopic methods that have been
used to estimate the amount dye in brain tissue (not to mention
the uncertainty about how much dye is bound to albumin and
other plasma proteins, how much to brain tissue and how much
may be free) (vi) in vivo potential lethal toxicity. Each of these
problems is considered in some detail in the next sections of this
review.
(I) Binding of Evans Blue (T-1824) and other
Dyes to Plasma Proteins: How Much Free
Dye is there?
Ehrlich (1885) suggested that the reason why some of the dyes,
which he studied in animals, did not appear in the urine was
that they might be bound to plasma albumin. This seems to
have been overlooked by the blood-brain barrier field until the
observations of Tschirgi (1950) on trypan blue and its exclusion
from the brain. He compared the lack of staining of the brain
when trypan blue was injected intravenously with the intense
staining of brain that occurred when the same concentration
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(0.2%) of the dye was injected dissolved in Tyrode solution. He
suggested that the lack of staining of the brain was due to binding
of the dye to plasma albumin, which he confirmed by adding
bovine albumin to the Tyrode-dye solution prior to injection.
The earliest suggestion that Evans blue and other related dyes
may bind to proteins in the blood appears to have been made
by Gregersen and Rawson (1943) and was studied in detail by
Rawson (1943) and by Allen and Orahovats (1950). Rawson
(1943) used the electrophoresis method of Tiselius (1937) to
study the binding of T-1824 (Evans blue) and structurally related
diazo dyes to proteins in human plasma and to investigate the
binding capacity of human albumin for T-1824 (Evans blue),
trypan blue (T-1826), Niagara sky blue 6B and Niagara sky blue.
In Rawson’s (1943) experiments at low concentrations (0.004%
or less) the dyes were wholly bound by albumin in either serum
or plasma. But at higher concentrations this was no longer the
case. Rawson (1943) estimated the binding capacity of human
albumin as 8–14 moles of T-1824 (Evans blue); Rawson also
found evidence for binding of the dye to globulins at higher
concentrations. From their measurements of T-1824 (Evans blue)
binding to albumin Allen and Orahovats (1950) showed that with
an injection of 4ml of 0.43% of the dye in a plasma volume and
albumin concentration corresponding to that in vivo there would
be measureable free dye (see Table 1).
Most studies using Evans blue to assess brain barrier integrity
have used 2% or 4% solutions (e.g., Petito, 1979; Wolman et al.,
1981; Abraham et al., 1996; Chen et al., 1996) thus at least when
first entering the bloodstream a proportion of the dye will be free.
An important aspect of Rawson’s (1943) study and that of Allen
andOrahovats (1950), which is almost universally ignored, is that
as the dye concentration was increased an increasing proportion
of the dye was free (i.e., not bound to albumin).
In blood-brain barrier experiments the volume injected is
usually given, but rarely the size of the animals used, so it is
often not possible to calculate the likely plasma concentration of
the dye. However, a few papers do give the relevant information.
Kaya and Ahishali (2011) published a methodological review of
TABLE 1 | Effect of albumin (Alb) molar concentration on binding of Evans
blue dye (T-1824).
Albumin T-1824 Unbound T-1824 T-1824:Alb Unbound,
Molar conc. Molar conc. Molar conc. Molar ratio T-1824(%)
1.23E-04 3.50E-03 2.13E-03 28.5 60.9
3.77E-04 1.76E-03 5.42E-06 4.7 0.31
5.03E-04 8.80E-04 1.40E-06 1.7 0.16
5.77E-04 3.52E-04 4.37E-07 0.61 0.12
6.04E-04 1.76E-04 2.00E-07 0.29 0.11
6.27E-04 1.76E-05 1.91E-08 0.03 0.11
Data in the first three columns are from the study of Allen and Orahovats (1950) in which
4ml of a 0.43% solution of T-1824 was mixed with different volumes of a 4.4% albumin
solution. At a ratio of 28.5 moles of T-1824 per mole of albumin, only around 40% of the T-
1824 is actually bound to albumin (i.e., each albuminmolecule binds amaximum of around
10 molecules of T-1824). Note that at all molar ratios less than this maximum binding
capacity, a small proportion of T-1824 (0.11–0.31%) remains free in solution unbound to
albumin.
various blood-brain barrier integrity markers including Evans
blue. In their description they indicate the use of 2% Evans
blue dissolved in “physiological” saline solution administered
intravenously at a dose of 4ml per Kg body weight of
animal. From this information the plasma concentration can be
calculated assuming that all of the injected dye mixes with plasma
before any significant losses, a haematocrit of 45% and a blood
volume of 8% body weight for different species. This gives a dye
concentration in plasma of 1.82mg/ml or 0.18%. In rats the blood
volume has been estimated as 6.44ml/100 g (Lee and Blaufox,
1985) and the albumin concentration around 2250mg/100ml or
22.5mg/ml (Dziegielewska et al., 1981). Thus, in this species, the
plasma dye concentration would be 2.17mg/ml (0.217%) at an
Evans blue: albumin molar ratio of 6.52.
Spigelman et al. (1983) used 0.5ml of a 2% Evans blue
simultaneously with sodium fluorescein and 99mTc-DTPA
injected i.v. into 200–250 g rats; as all of these bind to plasma
proteins it is likely there might have been some interference
with the binding of Evans blue to albumin. However, assuming
that this was not significant, the plasma concentration of Evans
blue can be calculated as 1.12mg/ml (0.11%) at an Evans blue:
albumin molar ratio of 3.37.
Using an in vitro test of albumin concentration on the
binding of Evans blue to cellophane, Rawson (1943) estimated
a maximum binding capacity of less than 14 molecules of
Evans blue per molecule of albumin. The data from Allen
and Orahovats (1950) investigating the effect of albumin
concentration on binding of Evans blue suggests a maximum
binding capacity of 10 molecules of Evans blue per molecule
of albumin (see Table 1). In both the Kaya and Ahishali (2011)
and Spigelman et al. (1983) studies, the plasma concentration
of Evans blue would probably not have exceeded the theoretical
maximum binding capacity of albumin. However, an important
point to note from the Allen and Orahovats (1950) study is
that even at very low Evans blue: albumin ratios (<1.0) a small
proportion of Evans blue always remains unbound to albumin
(see Table 1).
Moos and Møllgård (1993) re-investigated the problem of
free dye following intraperitoneal or subcutaneous injections
of different amounts of either trypan blue or Evans blue in
mice. For concentrations of Evans blue of 1 or 2% in 0.9%
saline (0.08ml/20 g body weight) they found spectrophotometric
evidence of substantial amounts of free dye in plasma at 30min
and 6 h following injection. For example using a 2% compared to
0.5% solution of Evans blue there was about 70% more free dye
at 6 h after injection. On examining the brains of mice injected
with this higher concentration of Evans blue, the dye was detected
intraneuronally at several sites in the brain. Moos and Møllgård
(1993) suggested a number of pathological mechanisms by which
free dye might have entered the brain in their experiments and
those of others.
Thus, it seems likely that there would bemeasureable amounts
of free dye when concentrations of 2 or 4%were used, particularly
in the first minutes after injection. That dye would be expected to
rapidly enter the extracellular space of many tissues and bind to
cells and matrix that have a higher affinity for Evans blue than the
proteins in plasma.
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(ii) Evans Blue does not Bind Exclusively to
Albumin in Plasma
It is widely claimed that Evan blue binds tightly and exclusively
to plasma albumin and that its visualization and/or quantitation
can be used to define increases in blood brain barrier permeability
to albumin (Wolman et al., 1981; Kitagawa et al., 1991; Nagaraja
et al., 2008). As evidence some authors refer to Rawson (1943)
but in most cases they simply refer to an earlier paper making
this claim (e.g., Kang et al., 2013 refer to Spigelman et al., 1983
who do not actually mention Evans blue binding to albumin).
Consideration of the literature on use of Evans blue for plasma
volume measurements shows that such a claim is not supported
by the experimental evidence. There are important species
differences in the specificity and tightness of the binding and
of particular importance is the fact that the binding of the dye
to albumin (and other proteins, including tissue proteins) is
a reversible equilibrium. Most of the original studies of Evans
blue as a plasma marker were carried out in humans and dogs,
species where the dye binding to albumin appears to be the
strongest (Alle et al., 1953; Reeve, 1957). However, even in these
species there were significant discrepancies in plasma volume
measurements made with Evans blue (assumed to be bound to
albumin) and with I125-albumin, suggesting that not all of the
injected dye became bound to protein in the blood; thus “Evans
blue-albumin” was found to have a larger distribution volume
than I125-albumin (Carvalho, 1989). In some species e.g., rabbits,
the discrepancy was even larger (Zizza and Reeve, 1958). The
most cited study of Evans blue binding to albumin is that of
Rawson (1943) who examined the binding to human albumin
at different dye concentrations in vitro (not in vivo as stated
by some authors; e.g., Uyama et al., 1988). However, Rawson
used human albumin for which the binding of Evans blue is
much tighter than for many animal species including rats (Alle
et al., 1953; Emmett et al., 1985); at the concentrations used
the dye would have been bound to other proteins in plasma
(Rawson, 1943; LeVeen and Fishman, 1947; Emmett et al.,
1985). This can be deduced from studies showing that Evans
blue can bind to other proteins in plasma including globulins
(LeVeen and Fishman, 1947), the post-albumin fraction (Linder
and Heinle, 1982) as well as α1-1ipoprotein, hemopexin, and
transferrin (Emmett et al., 1985). This is illustrated in Figure 4,
where the authors used the elegant but little applied technique
of crossed immunoeletrophoresis originally devised by Laurell
(1965). The binding to plasma proteins in commonly used
experimental animal species appears to be less tight than for
human albumin (Alle et al., 1953; Emmett et al., 1985) and at
the concentrations of the injected dye the binding capacity of
albumin is likely to be exceeded, as discussed in the previous
paragraph. As long ago as 1982 Linder and Heine concluded,
“at the concentrations used by many investigators areas dyed by
Evans blue may not be equated with the presence of diffusible
protein-dye complexes.” This is a good, if neglected, summary
of the problem. Because there is good evidence, as outlined
above that Evans blue does not bind exclusively to albumin,
its detection cannot be equated with the presence of albumin,
especially as albumin in many cases is much better visualized
using immunohistochemistry.
FIGURE 4 | Evans blue binding to 1, α1-lipoprotein; 2, albumin; 4,
hemopexin; 5, prealbumin; 6, α1X and 8, transferrin. Identified by anodal
shifts. From Figure 3 in Emmett et al. (1985).
(iii) Appropriate Carrier Solutions for Evans
Blue
According to Gregersen and Stewart (1938) Evans blue is not
stable in “saline” solutions unless some protein is also present.
They do not present any evidence for this, but given their
extensive experience of working with the dye it seems appropriate
to take note of this possible concern. Gregersen’s group generally
appears to have used water as the vehicle.
Some of the earlier studies, particularly those in which Evans
blue was used to estimate plasma volume (e.g., Carvalho, 1989)
the dye was mixed with plasma before injection. However,
most if not all of the many studies of blood-brain barrier
integrity published over the past 60 years appear to have used
a “physiological solution” as the carrier (e.g., Ribatti et al., 1993;
Kaya and Ahishali, 2011; Manaenko et al., 2011; Jiang et al., 2014)
and in some there is no mention of the solution in which the
Evans blue was dissolved (Kitagawa et al., 1991; Dhillon et al.,
1999; Whalen et al., 1999; Stahel et al., 2000). In summary,
the stability of Evans blue in many of the blood-brain barrier
experiments is unclear.
(iv) Tissue Binding of Albumin
The binding of Evans blue to albumin is an equilibrium, so an
additional factor to consider is the affinity of tissues with which
the dye may be exchanged from that bound to albumin (LeVeen
and Fishman, 1947). This has been little investigated, but it has
been shown in the aorta and common carotid arteries (Linder
and Heinle, 1982) and in the lungs (Dallal and Chang, 1994) that
in addition to binding to albumin a significant amount of the dye
is tightly bound to the tissue. The most extensive study of tissue
binding of Evans blue appears to be that of Clasen et al. (1970)
which will be discussed in detail in the next section because of its
particular relevance to attempts to quantitate Evans blue in brain
tissue, as a measure of blood-brain barrier dysfunction.
(v) Quantitation of Blood-Brain Barrier
Disruption using Evans Blue
The most problematic use of Evans blue in blood-brain
barrier studies is in attempts to use it to quantify the
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magnitude of a “leak” or barrier dysfunction. This is usually
done by extracting Evans blue from brain tissue at various
times following intravenous or intra-arterial dye injection.
Different solvents have been used to extract the dye and the
amount of dye in the brain extract estimated colorimetrically,
spectrophotometrically, or fluoro-spectrometrically (Evans blue
exhibits natural fluorescence). There are several problems in
addition to the ones discussed above concerning whether Evans
blue in brain is bound to plasma proteins (and which ones) or
is free and the extent to which the dye may have exchanged
with brain substance or has entered cells. Colorimetric and
spectrophotometric measurements are heavily dependent on the
standards used because Evans blue shows spectral shifts when
in protein-containing solutions. This is something that exercised
physiologists considered when they were developing Evans blue
for measurement of blood volume (Gregersen, 1938). These
problems are likely to be worse with brain extracts because
of the heterogeneity of the material compared with plasma
and differences between pathological and normal brain tissue
if the latter is used for standard Evans blue solutions (Hellal
et al., 2004). As mentioned above many authors do not mention
the composition of the standard solution used for Evans blue
determinations e.g., Dhillon et al. (1999), Whalen et al. (1999),
and Stahel et al. (2000). Evans blue has been suggested to be
unstable in “saline” or other salt solutions, unless some protein
is also present, which is why earlier workers used water as the
vehicle (Gregersen and Stewart, 1938).
There is the further problem that some of the Evans blue
in brain samples will also be present in contaminating blood
inevitably trapped in brain capillaries. Some authors have
attempted to remove blood by perfusing the circulatory system
prior to removing brain samples. It is unclear how successful this
is and the possibility that the dye may be washed out of the brain
tissue itself does not seem to have been considered.
Estimating the size of blood-brain barrier breakdown
following trauma seems particularly problematic. The initial
“breakdown” is probably due to rupture of blood vessels as
occurs in injury to any tissue or organ in the body, rather than
dysfunction due to disruption of specific brain barrier properties
(Hellal et al., 2004). No one talks about, for example, blood-
muscle barrier disruption following limb trauma. There seems
to be general agreement that following brain trauma there is
a period of few hours when plasma proteins or other large
molecules will enter the brain tissue (Habgood et al., 2007) but
this probably has more to do with the time of vessel disruption
and subsequent clotting of blood in the injured area of brain than
actual barrier malfunction. Subsequently there is a period that
may last several days when the barrier is permeable to molecules
smaller than proteins (Habgood et al., 2007) as will be considered
further below. The presence of clots in the vessels at the site of a
brain injurymakes it unlikely that amarker solution will enter the
damaged region adequately. In the case of Evans blue estimates of
the size of a “leak” this is likely to add to the unsatisfactory nature
of attempts to quantitate the size of a barrier dysfunction using
this marker.
Wang and Lai (2014) have recently published a critique of the
use of Evans blue for quantitation of blood volume and blood
brain barrier “leaks.” They cite some of the early literature when
Evans blue was being developed for blood volume measurements
and claim that Evans blue is a commonly used tracer for
estimation of blood volume in humans, yet the most recent paper
they cite is that of Theron and Wilson (1949). As discussed
above, the use of Evans blue for that purpose was replaced by
better markers many decades ago. Wang and Lai (2014) assume
that Evans blue and albumin can be equated, which from the
extensive discussion above about its binding to other plasma
proteins and tissues, is clearly not the case. They state that it
is non-toxic, which as discussed in the next section is not the
case either, although toxicity depends on the amount of dye and
the concentrations used. They also state that Evans blue is not
taken up by cells, citing Gregersen et al. (1935). However, these
authors do not make such a statement. They suggest that Evans
blue may be absorbed by red cells, which might mean that it is
taken up but equally that it sticks to the surface of cells. More
relevant is the evidence mentioned above that Evans blue sticks
to tissues, some of which may have a higher affinity for the dye
than albumin. Wang and Lai (2014) cite Clasen et al. (1970) in
support of their assertion that “its [Evans blue] extravasation into
central and peripheral organs following a more prolonged time
period correlates with vascular leakage of serum albumin, and its
leakage into the brain parenchyma indicates blood-brain barrier
(BBB) disruption.” Yet Clasen et al. (1970) were at great pains
to explain and study experimentally the nature of binding of the
dye to albumin and to tissues (and the equilibrium nature of this
relationship) as well as citing evidence that Evans blue may be
taken up by astrocytes. Clasen et al. (1970) estimate that as much
as 15% of Evans blue in some tissues is free dye bound to tissue
components, such as connective tissue. They state unequivocally
that “. . . .. the degree of coloration is not simply a reflection of the
total albumin content of the tissue.”
Thus, the published estimates of the size of blood-brain barrier
impairment or “leakage” are unreliable. However, some of the
concerns outlined here would apply equally to other markers,
particularly in the case of traumatic damage to the blood-brain
barrier.
(vi) Toxicity of Evans Blue in vivo
It seems to have been little considered that Evans blue might have
toxic properties in vivo. In a brief report Gibson and Gregersen
(1935) found that rats injected with 45mg/Kg T-1824 (Evans
blue) showed decreased rate of growth and on autopsy were
found to havemultiple pulmonary emboli and intracellular dye in
renal epithelium and hepatic parenchyma. Malaowalla and Fong
(1962) injected four monkeys with different doses of Evans blue.
One receiving 25mg/Kg survived and was apparently normal.
The other three injected with 50, 100, or 200mg/Kg died within
days of injection. The only systematic study appears to be that
of Hueper and Ichniowski (1944) who reported on the long
term toxic effects of intravenously administration of different
dose levels in dogs, cats, rabbits and rats. Aqueous solutions
of 0.5% were used, which is in fact a lower concentration than
generally used in blood brain barrier experiments (2%). Rats
were given 1, 3, 5, or 10ml/Kg injections of the dye. Three of
ten animals in the two larger dose groups died at 1–3 months,
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with widespread pathological changes in the brain, lungs, heart
and liver. Other animals were killed at 6 months; about half of
those examined showed substantial degenerative lesions in the
epithelium of the seminiferous tubules. This was examined in
shorter-term experiments in which 25 rats were administered two
injections of 1ml of a 1% aqueous solution of Evans blue with
3 days between injections. Fourteen rats died within 14 days,
the survivors were killed and all animals examined histologically.
Nearly 50% of the 25 animals showed testicular degeneration
to varying degrees. Other organs were not commented upon,
but it seems unlikely that the animals would have died from
a sole pathology of testicular degeneration, suggesting other
severe pathology in response to the Evans blue injections. Many
blood-brain barrier experiments employ 4–5ml/Kg Evans blue
solutions in concentrations of 2% (e.g., Uyama et al., 1988;
Dhillon et al., 1994; Whalen et al., 1999; Kaya and Ahishali,
2011; Manaenko et al., 2011) but sometimes as high as 4%
(Jiang et al., 2014). The duration of the experiments is generally
much less than in Hueper and Ichniowski (1944), in the range
of 10min to 24 h. So it is unclear whether there would have
been histologically detectable lesions within that time span. There
appear to be no reports on this, apart from the observations of
Moos and Møllgård (1993) from which they concluded that the
Evans blue they could detect in brain a few hours after injecting
2% Evans blue into mice might be due to toxic effects on cerebral
endothelial or ependymal cells; this suggests that at the most
commonly used concentration of Evans blue (2%) there may well
have been toxic effects.
Thus, there is good reason to be concerned about possible
toxic effects of Evans blue in short-term experiments involving
the concentration of dye most commonly used (2%).
In summary, it seems that all of the frequently asserted
properties of Evans blue as an exclusive marker for plasma
albumin are sufficiently suspect as to make it unsuitable for use
in studies of blood-brain barrier integrity. Evans blue detected
in brain is likely to be a mixture of dye bound to plasma
proteins (which ones and the quantitative extent depending
upon the species), dye bound to brain tissue and free dye. This
point does not seem to have been specifically studied in the
brain, but as mentioned above, has been examined in the lungs,
following systemic injection of Evans blue dye (Dallal and Chang,
1994). There are other markers, which do not suffer from these
problems. It seems baﬄing that Evans blue continues to be used
so widely.
HORSERADISH PEROXIDASE IN
ASSESSMENT OF BRAIN BARRIER
PERMEABILITY
The first mention of horseradish peroxidase (HRP) exclusion
from the brain after injection of a solution into the circulation
appears to be that of Straus (1959) although he is rarely credited
with this observation. The introduction of HRP into blood-
brain barrier studies was an important technical achievement,
which led to significant advances in understanding blood-
brain barrier biology. Of particular note are the papers by
Karnovsky (1967), Reese and Karnovsky (1967), and Brightman
and Reese (1969). The importance of the introduction of
HRP is that the reaction product of this peroxidase can be
made electron-dense, so it is possible to visualize it at the
electron microscopical level. The paper of Brightman and Reese
(1969) involved both intravascular and intrathecal injection
experiments. This milestone paper established the ultrastructural
basis for the barrier at the cerebrovascular interface between
blood and brain. These detailed studies showed that the primary
barrier was the intercellular tight junction between adjacent
endothelial cells although an additional barrier feature was the
paucity of intracellular pinocytotic vesicles in the endothelial
cells. They also showed tight junctions between the epithelial
cells of the choroid plexus providing a barrier to HRP at the
blood-CSF interface. The experiments described in these papers
(Karnovsky, 1967; Reese and Karnovsky, 1967; Brightman and
Reese, 1969) were all performed in mice, with no reports of HRP
toxicity.
However, when different strains of rats (and also guinea pigs)
were used subsequently, some technical problems with HRP
became apparent. These were well understood by the people
who developed the use of HRP for permeability studies in
various tissues, most notably Graham and Karnovsky (1966)
and Cotran and Karnovsky (1967, 1968). It was demonstrated
that HRP can cause degranulation of mast cells with the release
of histamine and serotonin, which have been shown to affect
vascular permeability (Majno et al., 1961) in some commonly
used strains of rats (Cotran and Karnovsky, 1967) but not
in others (Cotran et al., 1968). In early studies of barrier
permeability these rat strains (e.g., Sprague-Dawley) were treated
with anti-histamine and anti-serotonergic agents (Cotran and
Karnovsky, 1968). However, in later studies this precaution seems
to have been overlooked by some (e.g., Farrell and Shivers, 1984;
Lotocki et al., 2009; Kaya and Ahishali, 2011; Cunningham et al.,
2014) or only antihistamines were used (Tanno et al., 1992;
Dietrich et al., 1994; Ueno et al., 2002). In other studies the
problem was avoided by using Wistar rats (Ugrumov et al., 1983;
Dietrich et al., 1993; Cevik et al., 2013) in which HRP has been
reported not to produce mast cell degranulation (Cotran et al.,
1968) although it is unclear whether Wistar rats were chosen
with this problem in mind. Given these studies were aimed at
evaluating blood-brain barrier permeability, in studies in which
no inhibitors were used in strains of rats that are known to
be sensitive to HRP, this throws the value of results from such
experiments in doubt. Even in mice deleterious effects of HRP
have been demonstrated, but they appear to be dose dependent
and possibly also on the type of HRP used. Thus, Clementi
(1970) showed that doses of 24mg/100 g in Swiss albino mice
affected lung capillary permeability, but not when 1mg/100 g
was used. Also in Wistar rats 5–10mg/100 g body weight HRP
(but not 1mg/100 g) resulted in profound hypotension due to
histamine release which could be inhibited by pre-treatment with
the antihistamine promethazine (Deimann et al., 1976). A wide
range of HRP doses has been used in both rats and mice, ranging
from 0.4mg/100 g body weight in Sprague–Dawley rats (Cotran
and Karnovsky, 1968) to 33mg/100 g in adult Wistar rats (Pluta
et al., 1994), 90mg/100 g in postnatal Wistar rats (Ugrumov et al.,
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1983) and 20–40mg/100 g in adult white mice (Brightman and
Reese, 1969).
Ototoxicity of HRP has been described in guinea pigs (Ross
et al., 1977). There is also evidence of anomalous permeability
results when comparing HRP with other barrier permeability
markers, which, as was suggested, could be due to membrane
damage (Mazariegos et al., 1984).
We suggest that an additional factor, which does not seem
to have been considered, is the possibility that anesthesia might
modify or mask the toxic responses to HRP, although we are not
aware of any evidence for this. Some of the early experiments
did not involve anesthesia because they were confined to tail
vein injections (e.g., Brightman and Reese, 1969), but later
experiments involved a range of volatile and injected anesthetic
agents. In addition, it often seems not to be appreciated that what
is visualized in electron microscopy of HRP-containing tissues
is the reaction product of the peroxidase, not the protein itself.
Which raises the possibility of diffusion artifacts resulting in a
distribution of the reaction product that may not reflect that of
the actual protein.
Overall it seems reasonable to be cautious about interpreting
the results of experiments using HRP, especially when large
doses were employed and there was no pre-treatment with
antihistamines.
MORE APPROPRIATE MARKERS OF
BLOOD-BRAIN BARRIER DYSFUNCTION
Radiolabeled Markers
The use of radiolabeled sucrose and inulin for blood-brain
barrier permeability studies was pioneered by three giants in
the blood-brain barrier field: Dixon Woodbury, Hugh Davson
and Bill Oldendorf (e.g., Reed and Woodbury, 1963; Reed et al.,
1964; Davson and Bradbury, 1965; Davson and Oldendorf,
1967; Oldendorf and Davson, 1967; Davson and Segal, 1969,
1996). An important advantage of these markers is that they
allow a quantitative determination of blood-brain or blood-CSF
permeability. However, experiments in which they are used need
to be designed carefully if spurious results are not to be obtained.
This includes (i) ensuring that steady-state plasma levels of maker
are achieved, (ii) that blood contamination of brain samples by
the marker is estimated and (iii) the retention of the isotopic label
on the marker is secure.
Sucrose is a small water-soluble molecule that is not
metabolized to a significant extent if injected parenterally. It
distributes in the extracellular space of most tissues and organs
of the body, but because of the limited permeability of the blood-
brain and blood-CSF barriers and the turnover of CSF, sucrose
does not reach a concentration in brain that reflects the true
extracellular space. This is a phenomenon Davson described
as the “sink effect” (see Davson and Segal, 1996). A better
estimate of brain extracellular space using labeled sucrose has
been obtained by a combination of intravascular administration
and perfusion through the ventricular system (Oldendorf and
Davson, 1967). Because sucrose is excreted via the kidneys, a
single injection causes a rapid rise in blood level, followed by a
rapid decline with mixing and distribution into the extracellular
fluid and then a slower but steady decline due to loss in the
urine. This means that unless measures are taken to maintain a
steady-state plasma level of marker results expressed as a ratio
brain/plasma or CSF/plasma, then the falling plasma level will
give rise to a spurious finding that these ratios increase over
the period of an experiment in some cases up to 24 h (e.g.,
Ferguson andWoodbury, 1969). As described in detail by Davson
in many papers and text books (e.g., Davson and Segal, 1996)
an approximately steady state level in plasma can be obtained
by nephrectomy and either continuous infusion or intermittent
injection of sucrose during the course of the experiment.
Plasma samples collected throughout the experiment can then
be used to calculate a time-weighted mean plasma concentration
for calculation of a ratio based on terminal brain and CSF
samples. Although nephrectomy might appear to be a severe
and unphysiological intervention, in short term experiments
lasting only a few hours it is probably not affecting the results
of such experiments. In fetal sheep, nephrectomy is unnecessary
as the kidneys are not yet producing much urine but similar
experiments with radiolabeled sucrose have been obtained (Evans
et al., 1974). With respect to CSF samples it is essential that the
samples are checked for blood contamination (see Habgood et al.,
1992). For brain samples an estimate of blood contamination is
important otherwise ratios will be inflated by the presence of
marker in blood within the brain sample. This can be achieved
by injecting a second marker a few minutes before the end of
an experiment. It is necessary for this marker be present in the
circulation long enough to mix properly but not to penetrate into
the brain to any measurable extent. Radiolabeled markers such
as 113mIndium, which binds to transferrin and has the advantage
of a very short half-life, have been used for this purpose (Evans
et al., 1974) but other markers such as radiolabeled albumin or
inulin would also be suitable. Some authors have attempted to
deal with the problem of blood contamination of brain samples
by perfusing the brain with some form of “physiological” solution
prior to removing the brain. It is not clear how successful this
is, particularly in experiments involving brain trauma where part
of the cerebral circulation will be obstructed by post trauma
blood coagulation within vessels. Care is also required to make
sure the radiolabel is exclusive to the marker in use and remains
attached to the marker molecule throughout the experiment.
Providing these factors are taken into consideration the use of
radiolabeled markers is a valuable way of obtaining a quantitative
estimate of any brain barrier dysfunction. Their disadvantage is
that the radiolabel cannot be visualized in tissue sections to a
satisfactory level of resolution, so the morphological nature of
the dysfunction cannot be ascertained. This problem has been
overcome by the use of biotin labeled dextrans (see below).
Endogenous and Exogenous Plasma
Proteins
Immunohistochemical detection in brain sections of proteins
in plasma such as albumin (e.g., Dziegielewska et al., 1991;
Liddelow et al., 2009; O’Shea et al., 2014) immunoglobulin (e.g.,
Garbuzova-Davis et al., 2012; O’Shea et al., 2014; Blair et al.,
2015) and fibrinogen (e.g., Bridges et al., 2014) has been used
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to visualize breaches in the blood-brain barrier. Endogenous
proteins have the advantage that they are already present in situ
and do not need to be injected thus avoiding potentially un-
physiological conditions. Their limitation is that once they have
entered the extracellular space of the brain they will continue
to diffuse and therefore are not a reliable index of the duration
or progression of the leak across brain barriers (Habgood
et al., 2007). This problem can be circumvented by injecting an
exogenous protein and detecting it with an antibody that does
not cross-react with the native protein or a fluorophor-labeled
albumin (Dziegielewska et al., 1991; Pelz et al., 2013; Lehmann
et al., 2014; Krueger et al., 2015). As will be discussed below
this method and any other involving visualization of a marker
at the light microscopical level, may be of insufficient resolution
to determine the cellular nature of the barrier disruption,
although it is common for dysfunction to be equated with
disruption of tight junctions (Jin et al., 2014). Equally changes
in immunostaining of tight junction proteins (often erroneously
described as changes in expression e.g., Lucke-Wold et al.,
2014) are often confused with changes in permeability. These
conclusions can only be reached if appropriate ultrastructural
studies are carried out in parallel. As will be discussed below, this
is rarely the case.
Sodium Fluorescein
Sodium fluorescein (376 Da) was the first visualizable small
molecular sized marker to be introduced into the blood-
brain barrier field (Hoffman and Olszewski, 1961; Malmgren
and Olsson, 1980). Unlike the more commonly used dyes
such as Evans blue, sodium fluorescein binds only weakly to
proteins and appears to be an effective low molecular weight
marker for brain barrier studies in contrast to dyes that
bind to proteins (Wolman et al., 1981). Kaya and Ahishali
(2011) have suggested that spectrophotofluorimetric sodium
fluorescein uptake measurements (excitation at 440 nm and
emission at 525 nm) may enable detection of more subtle
alterations in blood-brain barrier permeability when compared
to the use of radioactive tracers and may thus be a sensitive
indicator of early stages of barrier permeability. No specific
effects of sodium fluorescein on blood-brain barrier appear
to have been reported. The LD50 in mice was estimated
as 4738 ± 1.23mg/Kg body weight (Yankell and Loux,
1977) whereas the amount injected into mice for barrier
permeability experiments was only a fraction of this, for example
50mg/Kg body weight (Malmgren and Olsson, 1980). A single
dose of 500mg/Kg in pregnant mice was reported not to
have any embryotoxic or teratogenic effects (Salem et al.,
1979).
Thus, sodium fluorescein appears to be considerably less toxic
than Evans blue or HRP and unlike Evans blue shows only weak
binding to proteins in plasma, which given some justification for
it being the second (with HRP) most commonly used marker for
blood-brain barrier integrity (Figure 2).
Dextrans
These are complex branched polysaccharides made of many
glucose molecules. They consist of chains of lengths varying
from 3 to 2000 kDa. They are commercially available labeled
either with a fluorophor or biotin. An even smaller biotin labeled
molecule, ethylenediamine (286 Da) is also available. This is
smaller than sucrose (342 Da), which is a commonly used marker
for quantitative studies of brain barrier permeability. There were
early reports of dextran toxicity when injected into paws of
rats due to histamine and 5-hydroxytrypatamine release that
could be attenuated by the use of specific inhibitors (Rowley
and Benditt, 1956). There has been quite extensive research
on dextrans as potential plasma expanders in trauma cases or
other circumstances of substantial blood loss. Proper discussion
of this is outside the scope of this review. Suffice it to say
that the use of dextrans clinically is limited by a significant
incidence of anaphylactoid reactions (Lundsgaard-Hansen, 1969;
Medby, 2014) and coagulopathy due to interference with some
of the clotting factors (Hahn, 2013; Medby, 2014) although this
property has been put to good use in prevention and treatment
of deep vein thrombosis (Medby, 2014). In animal experiments
it was shown that release of histamine and 5-hydroxytryptamine
occurs frommast cell degranulation as also reported for HRP (see
above). In rabbits administered intravenous dextran preparations
over several weeks, there were toxic effects following daily doses
of 20 mg/Kg body weight, but not with 10mg/Kg (Hint and
Richter, 1958). There are reports that the anaphylactoid effect
of dextrans depended on the preparation and is less in smaller
molecular weight preparations (Edlund et al., 1952; Walton,
1954); it is unclear to what extent the effects may have been
due to contaminants. The biotin and fluorophor labeled dextrans
now in experimental use are highly purified and because of
the sensitivity of the techniques applied to visualize the labels,
only small amounts are required. In our experience we have
not seen any untoward effects in vivo (e.g., Ek et al., 2001,
2003).
FIGURE 5 | Electron micrographs of the localization of biotin
ethylenediamine (BED) in blood vessels deep inside the cortex of a
2-month-old opossum 10min after an intravenous injection. Similar
staining is found after an intravenous injection of biotin-dextran (BDA3000). (A)
Low-power micrograph showing two paired vessels with abundant reaction
product within lumen. No reaction product is visible in the surrounding tissue.
Pairs of arteries and veins are characteristic of the vascular pattern in
marsupial brains (Wislocki and Campbell, 1937). (B) High-power micrograph
of an interendothelial cleft showing that the tight junctions in the young adult
restrict the passage of BED through the cleft (arrowhead). Scale bar = 4µm in
(A); 300 nm in (B). From Ek et al. (2006).
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Biotin labeled molecules can be visualized both at the light
microscopical and electron microscopical level (Ek et al., 2003,
2006; Johansson et al., 2006) as illustrated in Figure 5. The blood-
CSF permeability characteristics of a range of different sized
biotin labeled dextrans (and biotin ethylenediamine) have been
shown in quantitative studies to be similar to the permeability
of more traditional permeability markers, L-glucose, sucrose and
inulin and to be consistent with diffusion across the blood-
CSF interface (Ek et al., 2001, 2006). Use of fluorophor and
biotin labeled dextrans led to the unexpected finding that in the
developing and adult choroid plexus the route of entry from
blood to CSF is an intracellular one via the plexus epithelial cells
(Ek et al., 2003; Liddelow et al., 2009), as illustrated in Figure 6
rather than intercellular via the tight junctions as generally
believed (Anderson, 2001; Nitta et al., 2003; Piontek et al., 2008;
Abbott et al., 2010).
In summary, labeled dextrans are valuable markers of blood-
brain barrier integrity, which in the small concentrations used
appear to be non-toxic. The biotin labeled form is particularly
valuable as it can be visualized at both the light and electron
microscopical level. Also they can be quantitated in CSF (Ek et al.,
2006).
FIGURE 6 | Cellular localization of dextran probes in postnatal lateral
ventricular choroid plexus of the marsupial South American opossum
(Monodelphis domestica). (A) Forty-five minutes after intraperitoneal
injection with BDA-3 kDa, the probe can be seen in individual epithelial cells of
the choroid plexus (filled arrow), as well as in the blood vessel lumen
(arrowhead) and precipitated in the CSF (unfilled arrow). (B) Ten minutes after
intraventricular injection with BDA-3 kDa–Fluorescein, more epithelial cells take
up the probe (filled arrows) following CSF injection compared with
intraperitoneal injection (A). Penetration of the fluorescent probe between
epithelial cells is stopped by the presence of tight junctions (examples
highlighted by arrowheads). Scale: 50µm. From Liddelow et al. (2009).
BLOOD-BRAIN BARRIER DYSFUNCTION
IN NEUROLOGICAL DISORDERS
In the past 10–15 years there has been a resurgence of interest in
the possibility that the disruption or malfunction of the blood-
brain barrier may be involved in a wide range of neurological
disorders: (Keep et al., 2014) including dementia (van de Haar
et al., 2015) Alzheimer’s disease (Provias and Jeynes, 2014),
multiple sclerosis (Lengfeld et al., 2014; Kamphuis et al., 2015),
stroke (Schoknecht et al., 2014; Cui et al., 2015), diabetes (Liu
and Liu, 2014; Prasad et al., 2014) and trauma to the brain (Barzó
et al., 1997; Whalen et al., 1998; Stahel et al., 2000; Habgood
et al., 2007) and spinal cord (Oudega, 2012; Figley et al., 2014).
However, it is often not clear whether barrier dysfunction is
involved in the primary pathology or as a consequence of the
pathology, perhaps exacerbating the effects of the disorder. There
is generally a rather simple assumption that the barrier may be
breached, rather than considering the nature of the breach or the
possibility that the many cellular transport mechanisms (in and
out of the brain)might be affected. It is perhaps the simple view of
the blood-brain barrier as a mere mechanical barrier that has led
to such widespread use of Evans blue, without any realization of
its limitations as discussed above or the nature of the functional
mechanisms that may be affected.
More recent studies are beginning to examine specific barrier
mechanisms in neurological disorders, for example Cui et al.
(2015) claimed to demonstrate that ATP-binding cassette, ABC1
(cholesterol eﬄux pump) deficiency in stroke induced in mice
increased blood-brain barrier leakage of immunohistochemically
detected extravascular albumin. However, what they actually
showed was an association between ABCA1 deficiency and
albumin leakage; as they did not do high-resolution microscopy
they did not demonstrate the pathway across which the albumin
leakage occurred. More importantly there are likely to have been
many other transporter changes consequent upon the ischaemic
injury, which could have contributed to the barrier dysfunction.
The importance of this study is the demonstration of a change in
a transporter, rather than a leakage of protein, which is already
well known to occur in stroke (Krueger et al., 2015). Liu and
Liu (2014) have summarized studies showing that a number of
ABC transporters change their expression levels in blood vessels
of brains of rats with induced diabetes, but there are differences
in regulation that depend both on the specific transporter and on
the brain region. A quite different disorder of blood-brain barrier
function is heterozygous mutation in the GLUT1/SLC2A1 gene,
resulting in GLUT1-deficiency syndrome (GLUT1-DS), which
manifests itself in infants as motor and mental developmental
delay, seizures, reduced head growth and a movement disorder
with ataxia, dystonia, and spasticity (Brockmann, 2009).
The study of Krueger et al. (2015) is particularly important
because it is one of the few to employ immunohistochemistry
of tight junction proteins and electron microscopy of the
distribution of a barrier marker (FITC-albumin). They showed
that there was no change in either the tight junction proteins or
the ultrastructure of the junctions post stroke in adult rats. They
demonstrated that disruption of the blood-brain barrier resulted
in FITC-albumin-containing transendothelial vesicle trafficking
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TABLE 2 | Characteristics of blood-brain barrier markers described in this review.
Marker Size Binding1 Visualization Quantification3,4 Toxic5 Renal Cost
clearance6
Da Radius nm Protein Tissue2 Macro LM EM
Biotin ethylenediamine 286a NR NR No No Yes Yes Qualitative only NR Yes Med
Radio-sucrose 342.3b 0.51i No No No No No Accurate No Yes High
Na fluorescein 376c NR Weak NR No Yes No Unreliable No Yes Low
Evans blue 960d NR Yes Yes Yes Yes No Unreliable Yes No* Low
Trypan blue 961e NR No Yes Yes Yes No Unreliable Yes No* Low
Radio-inulin ≈7000b 1.3i No No No No No Accurate No Yes High
Horseradish peroxidase ≈44,000f 3.0j NR NR No Yes Yes Unreliable Yes No Low
Albumin (unlabeled) 69,000g 3.5i No No No IHC Yes Unreliable No No Low
Radio-albumin 69,000g 3.5i No No No IHC No Accurate No No High
IgG ≈155,000g 5.3i No No No IHC No Qualitative only No No Low
Fibrinogen 340,000g 11.0k No No No IHC No Qualitative only No No Low
Dextrans 1500 to 2,000,000h 0.8–38.2l NR NR No Yes Yes Qualitative in tissue No Only low MW High
MW, molecular weight; Macro, visible to unaided eye; LM, light microscopy; EM, electron microscopy; NR, not reported; IHC, immunohistochemistry; Med, medium cost; *unless protein
binding capacity in plasma exceeded.
a Ek et al. (2006), bWeast (1986), cMalmgren and Olsson (1980), dAllen and Orahovats (1950), eT1826, isomer of Evans blue, Allen and Orahovats (1950), fwww.sigmaaldrich.com,
gThompson (2005), hhttp://www.thermofisher.com, iDziegielewska et al. (1979), jRennke et al. (1978), kBoyd et al. (1969), lArmstrong et al. (2004), Grznárová et al. (2005).
1Dyes are generally problematic because they bind to proteins in plasma and to tissues in a reversible equilibrium, so when visualized it is unclear whether they are free dye or bound
dye and how they became located at a particular site.
2Many markers may be taken up by a variety of cells, including choroid plexus epithelial cells. Also neurons and glia, but only if the blood-brain barrier is breached.
3With currently available methods only markers with radiolabels (e.g., 3H, 14C, 125 I) can be reliably quantitated. For reliable measurements this requires checking on the stability of the
label and absence of contaminating labeled products (Evans et al., 1974). For liquid scintillation counting of 3H and 14C particular care is required to allow for differential quenching from
variations in protein content of samples; internal quench correction is usually inadequate. Colorimetric and spectrophotometric methods are generally inaccurate because of spectral
shifts produced by different composition of brain tissue and standards.
4Many groups attempt to deal with the problem of blood contamination by perfusing the cerebral circulation with “physiological” solutions at the termination of the experiment; this is
probably variably effective, particularly in the case of any local disturbance to cerebral circulation e.g., brain trauma, as local intravascular coagulation will limit entry of both marker and
of washout fluid.
5At concentrations used in marker experiments.
6Depends on molecular diameter, charge and protein binding. Dyes that bind to proteins in plasma would not be expected to appear in urine unless the concentration in plasma
exceeded the binding capacity of the proteins. Neutral substances with effective molecular diameters of <4 nm are freely filtered. Above 8 nm filtration is negligible. Between these
values the amount filtered depends on molecular diameter and charge (Barrett et al., 2012).
and signs of degeneration. These findings make it clear that
the common assumption that a leakage of marker (often Evans
blue) and/or down regulation of tight junction proteins are not
synonymous with disruption of tight junctions. For this to be
established requires ultrastructural studies using suitable electron
dense permeability markers or ones that can be rendered electron
dense by suitable processing (Ek et al., 2003, 2006).
CONCLUSIONS
The properties, advantages and disadvantages of the various
markers discussed above are summarized in Table 2. For
the many reasons outlined in this review, Evans blue is an
unsatisfactory tool for studying blood-brain barrier dysfunction.
The most that can be said in its favor is that it may be useful
in some circumstances as a rapid and inexpensive method for
checking for the presence of a barrier leak. But for proper
understanding of a barrier disruption there are now much better
methods available and its seems reasonable to propose that Evans
blue has had its day and is long overdue to be pensioned off from
brain barrier studies as happened long ago for its use for blood
volume estimates.
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